Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.
2.

Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.

Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, Amini RM, Botling J, Børresen-Dale AL, Sørlie T, Wärnberg F.

Mol Oncol. 2010 Aug;4(4):357-68. doi: 10.1016/j.molonc.2010.06.007.

3.

Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.

Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, Reyal F, Radvanyi F, Salmon R, Thiery JP, Sastre-Garau X, Sigal-Zafrani B, Fourquet A, Delattre O; breast cancer study group of the Institut Curie..

Clin Cancer Res. 2008 Apr 1;14(7):1956-65. doi: 10.1158/1078-0432.CCR-07-1465.

4.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.

5.

Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.

Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL.

Br J Cancer. 2011 Jan 4;104(1):120-7. doi: 10.1038/sj.bjc.6606021.

6.

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.

Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale AL.

BMC Genomics. 2006 May 26;7:127.

7.

Prediction consistency and clinical presentations of breast cancer molecular subtypes for Han Chinese population.

Huang CC, Tu SH, Lien HH, Jeng JY, Liu JS, Huang CS, Wu YY, Liu CY, Lai LC, Chuang EY.

J Transl Med. 2012 Sep 19;10 Suppl 1:S10. doi: 10.1186/1479-5876-10-S1-S10.

8.

Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups.

Kurian AW, Fish K, Shema SJ, Clarke CA.

Breast Cancer Res. 2010;12(6):R99. doi: 10.1186/bcr2780.

9.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059.

PMID:
23240985
10.

Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.

Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM.

Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157.

11.
12.

Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samples.

Dvorkin-Gheva A, Hassell JA.

PLoS One. 2011;6(10):e26023. doi: 10.1371/journal.pone.0026023.

13.

Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.

Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger AM.

Anticancer Res. 2003 May-Jun;23(3A):2043-51.

PMID:
12894577
14.

Molecular subtypes of ductal carcinoma in situ in African American and Caucasian American women: distribution and correlation with pathological features and outcome.

Sharaf Aldeen B, Feng J, Wu Y, Nassar Warzecha H.

Cancer Epidemiol. 2013 Aug;37(4):474-8. doi: 10.1016/j.canep.2013.03.018.

PMID:
23639792
15.

Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.

Chuthapisith S, Permsapaya W, Warnnissorn M, Akewanlop C, Sirivatanauksorn V, Prasarttong Osoth P.

Asian Pac J Cancer Prev. 2012;13(2):459-62.

16.

Gene expression profiling for breast cancer prognosis in Chinese populations.

Sun B, Zhang F, Wu SK, Guo X, Zhang LL, Jiang ZF, Wang DM, Song ST.

Breast J. 2011 Mar-Apr;17(2):172-9. doi: 10.1111/j.1524-4741.2010.01049.x.

PMID:
21410584
17.

Breast cancer stratification from analysis of micro-array data of micro-dissected specimens.

Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, Ganesan S, Delisi C, Bhanot G.

Genome Inform. 2007;18:130-40.

PMID:
18546481
18.

Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.

Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.

Neoplasma. 2012;59(4):424-32. doi: 10.4149/neo_2012_055.

PMID:
22489698
19.

Concurrent gene signatures for han chinese breast cancers.

Huang CC, Tu SH, Lien HH, Jeng JY, Huang CS, Huang CJ, Lai LC, Chuang EY.

PLoS One. 2013 Oct 3;8(10):e76421. doi: 10.1371/journal.pone.0076421.

20.

Challenges in projecting clustering results across gene expression-profiling datasets.

Lusa L, McShane LM, Reid JF, De Cecco L, Ambrogi F, Biganzoli E, Gariboldi M, Pierotti MA.

J Natl Cancer Inst. 2007 Nov 21;99(22):1715-23.

Items per page

Supplemental Content

Support Center